Hafizi Sassan, Wang Xuemin, Chester Adrian H, Yacoub Magdi H, Proud Christopher G
Department of Cardiothoracic Surgery, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, Heart Science Centre, Harefield Hospital, Middlesex, United Kingdom.
Am J Physiol Heart Circ Physiol. 2004 Sep;287(3):H1232-8. doi: 10.1152/ajpheart.00040.2004.
We have previously shown that the vasoconstrictive peptide angiotensin II (ANG II) is a hypertrophic agent for human coronary artery smooth muscle cells (cSMCs), which suggests that it plays a role in vascular wall thickening. The present study investigated the intracellular signal transduction pathways involved in the growth response of cSMCs to ANG II. The stimulation of protein synthesis by ANG II in cSMCs was blocked by the immunosuppressant rapamycin, which is an inhibitor of the mammalian target of rapamycin (mTOR) signaling pathway that includes the 70-kDa S6 kinase (p70(S6k)) and plays a key role in cell growth. The inhibitory effect of rapamycin was reversed by a molar excess of FK506; this indicates that both agents act through the common 12-kDa immunophilin FK506-binding protein. ANG II caused a rapid and sustained activation of p70(S6k) activity that paralleled its phosphorylation, and both processes were blocked by rapamycin. In addition, both of the phosphatidylinositol 3-kinase inhibitors wortmannin and LY-294002 abolished the ANG II-induced increase in protein synthesis, and wortmannin also blocked p70(S6k) phosphorylation. Furthermore, ANG II triggered dissociation of the translation initiation factor, eukaryotic initiation factor-4E, from its regulatory binding protein 4E-BP1, which was also inhibited by rapamycin and wortmannin. In conclusion, we have shown that ANG II activates components of the rapamycin-sensitive mTOR signaling pathway in human cSMCs and involves activation of phosphatidylinositol 3-kinase, p70(S6k), and eukaryotic initiation factor-4E, which leads to activation of protein synthesis. These signaling mechanisms may mediate the growth-promoting effect of ANG II in human cSMCs.
我们之前已经表明,血管收缩肽血管紧张素II(ANG II)是人类冠状动脉平滑肌细胞(cSMCs)的肥大因子,这表明它在血管壁增厚中起作用。本研究调查了cSMCs对ANG II生长反应所涉及的细胞内信号转导途径。免疫抑制剂雷帕霉素可阻断ANG II对cSMCs中蛋白质合成的刺激,雷帕霉素是哺乳动物雷帕霉素靶标(mTOR)信号通路的抑制剂,该信号通路包括70 kDa的S6激酶(p70(S6k)),并在细胞生长中起关键作用。雷帕霉素的抑制作用可被过量的FK506逆转;这表明这两种药物均通过共同的12 kDa亲免蛋白FK506结合蛋白起作用。ANG II引起p70(S6k)活性的快速持续激活,这与其磷酸化平行,且这两个过程均被雷帕霉素阻断。此外,磷脂酰肌醇3激酶抑制剂渥曼青霉素和LY-294002均消除了ANG II诱导的蛋白质合成增加,渥曼青霉素还阻断了p70(S6k)的磷酸化。此外,ANG II触发翻译起始因子真核起始因子-4E与其调节结合蛋白4E-BP1的解离,这也被雷帕霉素和渥曼青霉素抑制。总之,我们已经表明,ANG II激活人类cSMCs中对雷帕霉素敏感的mTOR信号通路的成分,并涉及磷脂酰肌醇3激酶、p70(S6k)和真核起始因子-4E的激活,从而导致蛋白质合成的激活。这些信号机制可能介导ANG II在人类cSMCs中的促生长作用。